Selected research
Market Analysis & Forecast
Global Recombinant Vaccines Market Analysis and Forecast 2026-2032
Market perspective
The global Recombinant Vaccines market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The North America market for Recombinant Vaccines is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Europe market for Recombinant Vaccines is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Read the full market overview
Asia-Pacific market for Recombinant Vaccines is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The China market for Recombinant Vaccines is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The major global companies of Recombinant Vaccines include Johnson & Johnson, Novartis AG, Merck & Co., Inc, Pfizer Inc., GlaxoSmithKline Plc., Bayer AG, AstraZeneca Plc., Serum Institute of India Pvt. Ltd and Sanofi S A., etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Recombinant Vaccines, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.
This report researches the key producers of Recombinant Vaccines, also provides the revenue of main regions and countries. Of the upcoming market potential for Recombinant Vaccines, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Recombinant Vaccines revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Recombinant Vaccines market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Recombinant Vaccines revenue, projected growth trends, production technology, application and end-user industry.
Recombinant Vaccines Segment by Company
Johnson & Johnson
Novartis AG
Merck & Co., Inc
Pfizer Inc.
GlaxoSmithKline Plc.
Bayer AG
AstraZeneca Plc.
Serum Institute of India Pvt. Ltd
Sanofi S A.
Protein Science Corporation
Novavax, Inc
Green Cross Corporation
Emergent BioSolutions Inc
Dynavax Technologies Corporation
Bharat Biotech
Recombinant Vaccines Segment by Type
Vector Recombinant Vaccines
Subunit Recombinant Vaccines
Attenuated Recombinant Vaccines
Recombinant Vaccines Segment by Application
Recombinant Human Vaccines
Animal Recombinant Vaccines
Recombinant Vaccines Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Recombinant Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Recombinant Vaccines in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Recombinant Vaccines company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Recombinant Vaccines revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Vector Recombinant Vaccines
- Subunit Recombinant Vaccines
- Attenuated Recombinant Vaccines
Applications
- Recombinant Human Vaccines
- Animal Recombinant Vaccines
Companies covered
- Johnson & Johnson
- Novartis AG
- Merck & Co., Inc
- Pfizer Inc.
- GlaxoSmithKline Plc.
- Bayer AG
- AstraZeneca Plc.
- Serum Institute of India Pvt. Ltd
- Sanofi S A.
- Protein Science Corporation
- Novavax, Inc
- Green Cross Corporation
- Emergent BioSolutions Inc
- Dynavax Technologies Corporation
- Bharat Biotech
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Recombinant Vaccines Market by Type
- 1.2.1 Global Recombinant Vaccines Market Size by Type, 2021 VS 2025 VS 2032
- 1.2.2 Vector Recombinant Vaccines
- 1.2.3 Subunit Recombinant Vaccines
- 1.2.4 Attenuated Recombinant Vaccines
- 1.3 Recombinant Vaccines Market by Application
- 1.3.1 Global Recombinant Vaccines Market Size by Application, 2021 VS 2025 VS 2032
- 1.3.2 Recombinant Human Vaccines
- 1.3.3 Animal Recombinant Vaccines
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Recombinant Vaccines Market Dynamics
- 2.1 Recombinant Vaccines Industry Trends
- 2.2 Recombinant Vaccines Industry Drivers
- 2.3 Recombinant Vaccines Industry Opportunities and Challenges
- 2.4 Recombinant Vaccines Industry Restraints
3 Global Growth Perspective
- 3.1 Global Recombinant Vaccines Market Perspective (2021-2032)
- 3.2 Global Recombinant Vaccines Growth Trends by Region
- 3.2.1 Global Recombinant Vaccines Market Size by Region: 2021 VS 2025 VS 2032
- 3.2.2 Global Recombinant Vaccines Market Size by Region (2021-2026)
- 3.2.3 Global Recombinant Vaccines Market Size by Region (2027-2032)
4 Competitive Landscape by Players
- 4.1 Global Recombinant Vaccines Revenue by Players
- 4.1.1 Global Recombinant Vaccines Revenue by Players (2021-2026)
- 4.1.2 Global Recombinant Vaccines Revenue Market Share by Players (2021-2026)
- 4.1.3 Global Recombinant Vaccines Players Revenue Share Top 10 and Top 5 in 2025
- 4.2 Global Recombinant Vaccines Key Players Ranking, 2024 VS 2025 VS 2026
- 4.3 Global Recombinant Vaccines Key Players Headquarters & Area Served
- 4.4 Global Recombinant Vaccines Players, Product Type & Application
- 4.5 Global Recombinant Vaccines Players Establishment Date
- 4.6 Market Competitive Analysis
- 4.6.1 Global Recombinant Vaccines Market CR5 and HHI
- 4.6.3 2025 Recombinant Vaccines Tier 1, Tier 2, and Tier 3
5 Recombinant Vaccines Market Size by Type
- 5.1 Global Recombinant Vaccines Revenue by Type (2021 VS 2025 VS 2032)
- 5.2 Global Recombinant Vaccines Revenue by Type (2021-2032)
- 5.3 Global Recombinant Vaccines Revenue Market Share by Type (2021-2032)
6 Recombinant Vaccines Market Size by Application
- 6.1 Global Recombinant Vaccines Revenue by Application (2021 VS 2025 VS 2032)
- 6.2 Global Recombinant Vaccines Revenue by Application (2021-2032)
- 6.3 Global Recombinant Vaccines Revenue Market Share by Application (2021-2032)
7 Company Profiles
- 7.1 Johnson & Johnson
- 7.1.1 Johnson & Johnson Company Information
- 7.1.2 Johnson & Johnson Business Overview
- 7.1.3 Johnson & Johnson Recombinant Vaccines Revenue and Gross Margin (2021-2026)
- 7.1.4 Johnson & Johnson Recombinant Vaccines Product Portfolio
- 7.1.5 Johnson & Johnson Recent Developments
- 7.2 Novartis AG
- 7.2.1 Novartis AG Company Information
- 7.2.2 Novartis AG Business Overview
- 7.2.3 Novartis AG Recombinant Vaccines Revenue and Gross Margin (2021-2026)
- 7.2.4 Novartis AG Recombinant Vaccines Product Portfolio
- 7.2.5 Novartis AG Recent Developments
- 7.3 Merck & Co., Inc
- 7.3.1 Merck & Co., Inc Company Information
- 7.3.2 Merck & Co., Inc Business Overview
- 7.3.3 Merck & Co., Inc Recombinant Vaccines Revenue and Gross Margin (2021-2026)
- 7.3.4 Merck & Co., Inc Recombinant Vaccines Product Portfolio
- 7.3.5 Merck & Co., Inc Recent Developments
- 7.4 Pfizer Inc.
- 7.4.1 Pfizer Inc. Company Information
- 7.4.2 Pfizer Inc. Business Overview
- 7.4.3 Pfizer Inc. Recombinant Vaccines Revenue and Gross Margin (2021-2026)
- 7.4.4 Pfizer Inc. Recombinant Vaccines Product Portfolio
- 7.4.5 Pfizer Inc. Recent Developments
- 7.5 GlaxoSmithKline Plc.
- 7.5.1 GlaxoSmithKline Plc. Company Information
- 7.5.2 GlaxoSmithKline Plc. Business Overview
- 7.5.3 GlaxoSmithKline Plc. Recombinant Vaccines Revenue and Gross Margin (2021-2026)
- 7.5.4 GlaxoSmithKline Plc. Recombinant Vaccines Product Portfolio
- 7.5.5 GlaxoSmithKline Plc. Recent Developments
- 7.6 Bayer AG
- 7.6.1 Bayer AG Company Information
- 7.6.2 Bayer AG Business Overview
- 7.6.3 Bayer AG Recombinant Vaccines Revenue and Gross Margin (2021-2026)
- 7.6.4 Bayer AG Recombinant Vaccines Product Portfolio
- 7.6.5 Bayer AG Recent Developments
- 7.7 AstraZeneca Plc.
- 7.7.1 AstraZeneca Plc. Company Information
- 7.7.2 AstraZeneca Plc. Business Overview
- 7.7.3 AstraZeneca Plc. Recombinant Vaccines Revenue and Gross Margin (2021-2026)
- 7.7.4 AstraZeneca Plc. Recombinant Vaccines Product Portfolio
- 7.7.5 AstraZeneca Plc. Recent Developments
- 7.8 Serum Institute of India Pvt. Ltd
- 7.8.1 Serum Institute of India Pvt. Ltd Company Information
- 7.8.2 Serum Institute of India Pvt. Ltd Business Overview
- 7.8.3 Serum Institute of India Pvt. Ltd Recombinant Vaccines Revenue and Gross Margin (2021-2026)
- 7.8.4 Serum Institute of India Pvt. Ltd Recombinant Vaccines Product Portfolio
- 7.8.5 Serum Institute of India Pvt. Ltd Recent Developments
- 7.9 Sanofi S A.
- 7.9.1 Sanofi S A. Company Information
- 7.9.2 Sanofi S A. Business Overview
- 7.9.3 Sanofi S A. Recombinant Vaccines Revenue and Gross Margin (2021-2026)
- 7.9.4 Sanofi S A. Recombinant Vaccines Product Portfolio
- 7.9.5 Sanofi S A. Recent Developments
- 7.10 Protein Science Corporation
- 7.10.1 Protein Science Corporation Company Information
- 7.10.2 Protein Science Corporation Business Overview
- 7.10.3 Protein Science Corporation Recombinant Vaccines Revenue and Gross Margin (2021-2026)
- 7.10.4 Protein Science Corporation Recombinant Vaccines Product Portfolio
- 7.10.5 Protein Science Corporation Recent Developments
- 7.11 Novavax, Inc
- 7.11.1 Novavax, Inc Company Information
- 7.11.2 Novavax, Inc Business Overview
- 7.11.3 Novavax, Inc Recombinant Vaccines Revenue and Gross Margin (2021-2026)
- 7.11.4 Novavax, Inc Recombinant Vaccines Product Portfolio
- 7.11.5 Novavax, Inc Recent Developments
- 7.12 Green Cross Corporation
- 7.12.1 Green Cross Corporation Company Information
- 7.12.2 Green Cross Corporation Business Overview
- 7.12.3 Green Cross Corporation Recombinant Vaccines Revenue and Gross Margin (2021-2026)
- 7.12.4 Green Cross Corporation Recombinant Vaccines Product Portfolio
- 7.12.5 Green Cross Corporation Recent Developments
- 7.13 Emergent BioSolutions Inc
- 7.13.1 Emergent BioSolutions Inc Company Information
- 7.13.2 Emergent BioSolutions Inc Business Overview
- 7.13.3 Emergent BioSolutions Inc Recombinant Vaccines Revenue and Gross Margin (2021-2026)
- 7.13.4 Emergent BioSolutions Inc Recombinant Vaccines Product Portfolio
- 7.13.5 Emergent BioSolutions Inc Recent Developments
- 7.14 Dynavax Technologies Corporation
- 7.14.1 Dynavax Technologies Corporation Company Information
- 7.14.2 Dynavax Technologies Corporation Business Overview
- 7.14.3 Dynavax Technologies Corporation Recombinant Vaccines Revenue and Gross Margin (2021-2026)
- 7.14.4 Dynavax Technologies Corporation Recombinant Vaccines Product Portfolio
- 7.14.5 Dynavax Technologies Corporation Recent Developments
- 7.15 Bharat Biotech
- 7.15.1 Bharat Biotech Company Information
- 7.15.2 Bharat Biotech Business Overview
- 7.15.3 Bharat Biotech Recombinant Vaccines Revenue and Gross Margin (2021-2026)
- 7.15.4 Bharat Biotech Recombinant Vaccines Product Portfolio
- 7.15.5 Bharat Biotech Recent Developments
8 North America
- 8.1 North America Recombinant Vaccines Revenue (2021-2032)
- 8.2 North America Recombinant Vaccines Revenue by Type (2021-2032)
- 8.2.1 North America Recombinant Vaccines Revenue by Type (2021-2026)
- 8.2.2 North America Recombinant Vaccines Revenue by Type (2027-2032)
- 8.3 North America Recombinant Vaccines Revenue Share by Type (2021-2032)
- 8.4 North America Recombinant Vaccines Revenue by Application (2021-2032)
- 8.4.1 North America Recombinant Vaccines Revenue by Application (2021-2026)
- 8.4.2 North America Recombinant Vaccines Revenue by Application (2027-2032)
- 8.5 North America Recombinant Vaccines Revenue Share by Application (2021-2032)
- 8.6 North America Recombinant Vaccines Revenue by Country
- 8.6.1 North America Recombinant Vaccines Revenue by Country (2021 VS 2025 VS 2032)
- 8.6.2 North America Recombinant Vaccines Revenue by Country (2021-2026)
- 8.6.3 North America Recombinant Vaccines Revenue by Country (2027-2032)
- 8.6.4 United States
- 8.6.5 Canada
- 8.6.6 Mexico
9 Europe
- 9.1 Europe Recombinant Vaccines Revenue (2021-2032)
- 9.2 Europe Recombinant Vaccines Revenue by Type (2021-2032)
- 9.2.1 Europe Recombinant Vaccines Revenue by Type (2021-2026)
- 9.2.2 Europe Recombinant Vaccines Revenue by Type (2027-2032)
- 9.3 Europe Recombinant Vaccines Revenue Share by Type (2021-2032)
- 9.4 Europe Recombinant Vaccines Revenue by Application (2021-2032)
- 9.4.1 Europe Recombinant Vaccines Revenue by Application (2021-2026)
- 9.4.2 Europe Recombinant Vaccines Revenue by Application (2027-2032)
- 9.5 Europe Recombinant Vaccines Revenue Share by Application (2021-2032)
- 9.6 Europe Recombinant Vaccines Revenue by Country
- 9.6.1 Europe Recombinant Vaccines Revenue by Country (2021 VS 2025 VS 2032)
- 9.6.2 Europe Recombinant Vaccines Revenue by Country (2021-2026)
- 9.6.3 Europe Recombinant Vaccines Revenue by Country (2027-2032)
- 9.6.4 Germany
- 9.6.5 France
- 9.6.6 U.K.
- 9.6.7 Italy
- 9.6.8 Russia
- 9.6.9 Spain
- 9.6.10 Netherlands
- 9.6.11 Switzerland
- 9.6.12 Sweden
- 9.6.13 Poland
10 China
- 10.1 China Recombinant Vaccines Revenue (2021-2032)
- 10.2 China Recombinant Vaccines Revenue by Type (2021-2032)
- 10.2.1 China Recombinant Vaccines Revenue by Type (2021-2026)
- 10.2.2 China Recombinant Vaccines Revenue by Type (2027-2032)
- 10.3 China Recombinant Vaccines Revenue Share by Type (2021-2032)
- 10.4 China Recombinant Vaccines Revenue by Application (2021-2032)
- 10.4.1 China Recombinant Vaccines Revenue by Application (2021-2026)
- 10.4.2 China Recombinant Vaccines Revenue by Application (2027-2032)
- 10.5 China Recombinant Vaccines Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
- 11.1 Asia Recombinant Vaccines Revenue (2021-2032)
- 11.2 Asia Recombinant Vaccines Revenue by Type (2021-2032)
- 11.2.1 Asia Recombinant Vaccines Revenue by Type (2021-2026)
- 11.2.2 Asia Recombinant Vaccines Revenue by Type (2027-2032)
- 11.3 Asia Recombinant Vaccines Revenue Share by Type (2021-2032)
- 11.4 Asia Recombinant Vaccines Revenue by Application (2021-2032)
- 11.4.1 Asia Recombinant Vaccines Revenue by Application (2021-2026)
- 11.4.2 Asia Recombinant Vaccines Revenue by Application (2027-2032)
- 11.5 Asia Recombinant Vaccines Revenue Share by Application (2021-2032)
- 11.6 Asia Recombinant Vaccines Revenue by Country
- 11.6.1 Asia Recombinant Vaccines Revenue by Country (2021 VS 2025 VS 2032)
- 11.6.2 Asia Recombinant Vaccines Revenue by Country (2021-2026)
- 11.6.3 Asia Recombinant Vaccines Revenue by Country (2027-2032)
- 11.6.4 Japan
- 11.6.5 South Korea
- 11.6.6 India
- 11.6.7 Australia
- 11.6.8 Taiwan
- 11.6.9 Southeast Asia
12 South America, Middle East and Africa
- 12.1 SAMEA Recombinant Vaccines Revenue (2021-2032)
- 12.2 SAMEA Recombinant Vaccines Revenue by Type (2021-2032)
- 12.2.1 SAMEA Recombinant Vaccines Revenue by Type (2021-2026)
- 12.2.2 SAMEA Recombinant Vaccines Revenue by Type (2027-2032)
- 12.3 SAMEA Recombinant Vaccines Revenue Share by Type (2021-2032)
- 12.4 SAMEA Recombinant Vaccines Revenue by Application (2021-2032)
- 12.4.1 SAMEA Recombinant Vaccines Revenue by Application (2021-2026)
- 12.4.2 SAMEA Recombinant Vaccines Revenue by Application (2027-2032)
- 12.5 SAMEA Recombinant Vaccines Revenue Share by Application (2021-2032)
- 12.6 SAMEA Recombinant Vaccines Revenue by Country
- 12.6.1 SAMEA Recombinant Vaccines Revenue by Country (2021 VS 2025 VS 2032)
- 12.6.2 SAMEA Recombinant Vaccines Revenue by Country (2021-2026)
- 12.6.3 SAMEA Recombinant Vaccines Revenue by Country (2027-2032)
- 12.6.4 Brazil
- 12.6.5 Argentina
- 12.6.6 Chile
- 12.6.7 Colombia
- 12.6.8 Peru
- 12.6.9 Saudi Arabia
- 12.6.10 Israel
- 12.6.11 UAE
- 12.6.12 Turkey
- 12.6.13 Iran
- 12.6.14 Egypt
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst